Home › Funds › Cormorant Asset Management, LP › ARTV
Cormorant Asset Management, LP position in ARTV
ARTIVA BIOTHERAPEUTICS INC · Health Care
Cormorant Asset Management, LP reported holding 1,815,740 shares of ARTV (ARTIVA BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$30.3M, representing 2.17% of its reported portfolio and ranking #16 among its reported holdings. Cormorant Asset Management, LP has disclosed ARTV holdings in 3 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's ARTV position evolved
Cormorant Asset Management, LP first disclosed a stake in ARTV in Q3 2024 at 103,633 shares (US$1.6M). The position peaked in Q3 2026 at 1,815,740 shares, worth US$30.3M. Across 3 filings, Cormorant Asset Management, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,815,740 shares valued at US$30.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 103.63K | $1.60M | New |
| Q4 2024 | 103.63K | $1.04M | Hold |
| Q3 2026 | 1.82M | $30.32M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARTV and 13F data
ARTV (ARTIVA BIOTHERAPEUTICS INC) is a Health Care company. 87 other funds we track also report a position in ARTV — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$220.2M), 5AM Venture Management, LLC (US$139.1M), Deep Track Capital, LP (US$73.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARTV
- RA CAPITAL MANAGEMENT, L.P. 23.79M sh · $220.20M · Q3 2026
- 5AM Venture Management, LLC 9.68M sh · $139.10M · Q3 2026
- Deep Track Capital, LP 4.41M sh · $73.62M · Q3 2026
- Blue Owl Capital Holdings LP 4.13M sh · $63.84M · Q3 2026
- Foresite Capital Management V, LLC 3.56M sh · $59.50M · Q3 2026
- Foresite Capital Management VI LLC 2.20M sh · $36.80M · Q3 2026
- ORBIMED ADVISORS LLC 1.68M sh · $27.98M · Q3 2026
- Venrock Adviser, LLC 2.04M sh · $14.55M · Q3 2026
- Sanofi 672.78K sh · $11.24M · Q3 2026
- Caligan Partners LP 1.48M sh · $10.55M · Q3 2026
- Samsara BioCapital, LLC 954.86K sh · $6.80M · Q3 2026
- Saturn V Capital Management LP 300.36K sh · $5.02M · Q3 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held ARTV?
Cormorant Asset Management, LP has disclosed ARTV holdings in 3 of the last 9 reported quarters, going back to Q3 2024.
What is Cormorant Asset Management, LP's current position in ARTV?
As of Q3 2026, Cormorant Asset Management, LP holds 1.82M shares of ARTV (ARTIVA BIOTHERAPEUTICS INC), valued at $30.32M, representing 2.17% of its reported portfolio and ranking #16.
Has Cormorant Asset Management, LP been buying or selling ARTV?
In the latest 13F filing (Q3 2026), Cormorant Asset Management, LP newly opened its position in ARTV. The position peaked in Q3 2026 at 1.82M shares.
Which other funds hold ARTV?
Other major institutional holders of ARTV include RA CAPITAL MANAGEMENT, L.P., 5AM Venture Management, LLC, Deep Track Capital, LP, among 87 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.